Noah L. Rosenberg

Insider · Cmo · VRCA

Noah L. Rosenberg files insider transactions with the SEC as a cmo of Verrica Pharmaceuticals (VRCA). We hold 2 disclosed purchases and sales filed since 25 July 2013, 2 of them in the last 90 days.

Files forVRCA
Disclosed buys and sells2 in all, 2 in the last 90 days
Last disclosure18 August 2026

Positions held

4 posts we hold — a term names its own dates; a run of filings only says when they filed

Filed 24 March 2025 — 18 August 2026Cmo · Verrica Pharmaceuticals (VRCA)6 Form 4 lines · source: SEC Form 4
Filed 21 January 2021 — 17 August 2021Chief Medical Officer · Travere Therapeutics (TVTX)15 Form 4 lines · source: SEC Form 4
Filed 26 July 2018 — 23 September 2020Chief Medical Officer · Retrophin (RTRX)19 Form 4 lines · source: SEC Form 4
Filed 23 July 2013 — 23 July 2013Chief Medical Officer · Esperion Therapeutics (ESPR)1 Form 4 line · source: SEC Form 4

Everything they disclosed

41 entries, newest first — one per disclosure report, one per Form 4 line

▲ bought on the open market 4,200 shares of Verrica PharmaceuticalsSEC Form 418 August 2026Common Stock · traded 17 August 2026 · filed 18 August 2026
▲ bought on the open market 2,030 shares of Verrica PharmaceuticalsSEC Form 418 August 2026Common Stock · traded 18 August 2026 · filed 18 August 2026
was granted 233,840 shares of Verrica Pharmaceuticals (a derivative holding)SEC Form 49 June 2026Employee Stock Option (right to buy) · traded 5 June 2026 · filed 9 June 2026
▲ bought on the open market 589 shares of Verrica Pharmaceuticals (a derivative holding)SEC Form 425 November 2025Series C Warrant (right to buy) · traded 25 November 2025 · filed 25 November 2025
▲ bought on the open market 2,357 shares of Verrica PharmaceuticalsSEC Form 425 November 2025Common Stock · traded 25 November 2025 · filed 25 November 2025
was granted 325,000 shares of Verrica Pharmaceuticals (a derivative holding)SEC Form 426 March 2025Employee Stock Option (right to buy) · traded 24 March 2025 · filed 26 March 2025
was granted 4,500 shares of Travere TherapeuticsSEC Form 417 August 2021Common Stock · traded 13 August 2021 · filed 17 August 2021
▼ sold on the open market 1,407 shares of Travere TherapeuticsSEC Form 417 August 2021Common Stock · traded 17 August 2021 · filed 17 August 2021
▼ sold on the open market 1,250 shares of Travere TherapeuticsSEC Form 429 July 2021Common Stock · traded 28 July 2021 · filed 29 July 2021
▼ sold on the open market 375 shares of Travere TherapeuticsSEC Form 413 May 2021Common Stock · traded 11 May 2021 · filed 13 May 2021
▼ sold on the open market 375 shares of Travere TherapeuticsSEC Form 413 May 2021Common Stock · traded 12 May 2021 · filed 13 May 2021
▼ sold on the open market 1,125 shares of Travere TherapeuticsSEC Form 49 February 2021Common Stock · traded 5 February 2021 · filed 9 February 2021
▼ sold on the open market 1,125 shares of Travere TherapeuticsSEC Form 49 February 2021Common Stock · traded 8 February 2021 · filed 9 February 2021
was granted 4,500 shares of Travere TherapeuticsSEC Form 45 February 2021Common Stock · traded 3 February 2021 · filed 5 February 2021
▼ sold on the open market 1,250 shares of Travere TherapeuticsSEC Form 43 February 2021Common Stock · traded 3 February 2021 · filed 3 February 2021
▼ sold on the open market 563 shares of Travere TherapeuticsSEC Form 43 February 2021Common Stock · traded 3 February 2021 · filed 3 February 2021
was granted 5,000 shares of Travere TherapeuticsSEC Form 42 February 2021Common Stock · traded 31 January 2021 · filed 2 February 2021
▼ sold on the open market 1,250 shares of Travere TherapeuticsSEC Form 42 February 2021Common Stock · traded 2 February 2021 · filed 2 February 2021
▼ sold on the open market 563 shares of Travere TherapeuticsSEC Form 42 February 2021Common Stock · traded 2 February 2021 · filed 2 February 2021
was granted 57,500 shares of Travere Therapeutics (a derivative holding)SEC Form 425 January 2021Employee stock option (right to buy) · traded 21 January 2021 · filed 25 January 2021
was granted 15,000 shares of Travere TherapeuticsSEC Form 425 January 2021Common Stock · traded 21 January 2021 · filed 25 January 2021
▼ sold on the open market 750 shares of RetrophinSEC Form 423 September 2020Common Stock · traded 23 September 2020 · filed 23 September 2020
was granted 3,000 shares of RetrophinSEC Form 422 September 2020Common Stock · traded 18 September 2020 · filed 22 September 2020
▼ sold on the open market 750 shares of RetrophinSEC Form 422 September 2020Common Stock · traded 22 September 2020 · filed 22 September 2020
▼ sold on the open market 870 shares of RetrophinSEC Form 430 July 2020Common Stock · traded 28 July 2020 · filed 30 July 2020
▼ sold on the open market 527 shares of RetrophinSEC Form 413 May 2020Common Stock · traded 12 May 2020 · filed 13 May 2020
was granted 5,000 shares of RetrophinSEC Form 49 March 2020Common Stock · traded 5 March 2020 · filed 9 March 2020
▼ sold on the open market 1,790 shares of RetrophinSEC Form 49 March 2020Common Stock · traded 5 March 2020 · filed 9 March 2020
was granted 55,000 shares of Retrophin (a derivative holding)SEC Form 431 January 2020Employee stock option (right to buy) · traded 31 January 2020 · filed 31 January 2020
was granted 9,000 shares of Retrophin (a derivative holding)SEC Form 431 January 2020Performance-based restricted stock units · traded 31 January 2020 · filed 31 January 2020
was granted 10,000 shares of Retrophin (a derivative holding)SEC Form 431 January 2020Performance-based restricted stock units · traded 31 January 2020 · filed 31 January 2020
was granted 9,000 shares of RetrophinSEC Form 431 January 2020Common Stock · traded 31 January 2020 · filed 31 January 2020
▼ sold on the open market 1,250 shares of RetrophinSEC Form 431 July 2019Common Stock · traded 30 July 2019 · filed 31 July 2019
▼ sold on the open market 1,250 shares of RetrophinSEC Form 431 July 2019Common Stock · traded 31 July 2019 · filed 31 July 2019
was granted 40,000 shares of Retrophin (a derivative holding)SEC Form 410 May 2019Employee stock option (right to buy) · traded 9 May 2019 · filed 10 May 2019
was granted 6,000 shares of Retrophin (a derivative holding)SEC Form 410 May 2019Performance-based restricted stock units · traded 9 May 2019 · filed 10 May 2019
was granted 6,000 shares of RetrophinSEC Form 410 May 2019Common Stock · traded 9 May 2019 · filed 10 May 2019
was granted 10,000 shares of RetrophinSEC Form 430 July 2018Common Stock · traded 26 July 2018 · filed 30 July 2018
was granted 65,000 shares of Retrophin (a derivative holding)SEC Form 430 July 2018Employee stock option (right to buy) · traded 26 July 2018 · filed 30 July 2018
was granted 10,000 shares of Retrophin (a derivative holding)SEC Form 430 July 2018Performance-based restricted stock units · traded 26 July 2018 · filed 30 July 2018
was granted 13,500 shares of Esperion Therapeutics (a derivative holding)SEC Form 425 July 2013Stock Option (right to buy) · traded 23 July 2013 · filed 25 July 2013

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.